E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Inflammatory Diseases and Viral Immune Modulating Protein Therapeutics"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: 20 July 2019

Special Issue Editor

Guest Editor
Prof. Dr. Alexandra Lucas

Centers for Personalized Diagnostics and Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ 85287-6401, USA
Website | E-Mail
Interests: serpin, chemokine, inflammation, transplant, vasculitis, glycosaminoglycans, wound healing, spinal cord injury

Special Issue Information

Dear Colleagues,

Viruses have developed highly effective immune modulating proteins through millions of years of evolution. These immune modulating proteins allow viruses to avoid and/or actively combat inflammatory and immune responses from the infected host that are designed to block viral invasion and proliferation. These highly evolved and efficient virus-derived immune modulating mechanisms are often very potent, working at low concentrations in the picomolar range and targeting key immune pathways. In prior work, we and other investigators have examined these unique proteins as a new source for biologics, protein and peptide therapeutics. With this series of papers, our intent is to illustrate and to explore the potential of virus-derived immune modulating proteins to provide new and highly effective therapeutic approaches to alter immune responses in disease.

Prof. Dr. Alexandra Lucas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Immune modulation
  • Inflammation
  • Virus
  • Protein
  • Chemokine
  • Serine protease inhibitors (serpin)
  • Tumor necrosis factor (TNF)
  • Interleukin 10 (IL10)
  • Inflammasome
  • Apoptosis

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Review

Open AccessReview
Immunoproteomic Lessons for Human Respiratory Syncytial Virus Vaccine Design
J. Clin. Med. 2019, 8(4), 486; https://doi.org/10.3390/jcm8040486
Received: 8 March 2019 / Revised: 1 April 2019 / Accepted: 9 April 2019 / Published: 10 April 2019
PDF Full-text (998 KB) | HTML Full-text | XML Full-text
Abstract
Accurate antiviral humoral and cellular immune responses require prior recognition of antigenic peptides presented by human leukocyte antigen (HLA) class I and II molecules on the surface of antigen-presenting cells. Both the helper and the cytotoxic immune responses are critical for the control [...] Read more.
Accurate antiviral humoral and cellular immune responses require prior recognition of antigenic peptides presented by human leukocyte antigen (HLA) class I and II molecules on the surface of antigen-presenting cells. Both the helper and the cytotoxic immune responses are critical for the control and the clearance of human respiratory syncytial virus (HRSV) infection, which is a significant cause of morbidity and mortality in infected pediatric, immunocompromised and elderly populations. In this article we review the immunoproteomics studies which have defined the general antigen processing and presentation rules that determine both the immunoprevalence and the immunodominance of the cellular immune response to HRSV. Mass spectrometry and functional analyses have shown that the HLA class I and II cellular immune responses against HRSV are mainly focused on three viral proteins: fusion, matrix, and nucleoprotein. Thus, these studies have important implications for vaccine development against this virus, since a vaccine construct including these three relevant HRSV proteins could efficiently stimulate the major components of the adaptive immune system: humoral, helper, and cytotoxic effector immune responses. Full article
Figures

Figure 1

J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top